How does ibogaine work?

Evidence level: C Emerging evidence — observational studies and case series, no randomised controlled trials yet. We say so wherever it matters.

Ibogaine works in three connected ways. Once taken, the liver converts it into noribogaine, a long-acting metabolite; both compounds reach the brain, where they act on a wide range of receptor systems including opioid receptors — which is why physical withdrawal typically stops within the first hours of a session. Cravings fall away at the same time. And for many hours afterwards the patient remains in a prolonged introspective state that makes psychological work unusually accessible.

That third part is easy to underestimate and is arguably the most important. Ibogaine does not repair a person’s relationship with their addiction by itself. It removes the two forces — withdrawal and craving — that normally make that work impossible, and holds them off long enough for something else to happen.

What happens in the body

Ibogaine is not the main active agent for long. After administration it passes through the liver, where it is metabolised into noribogaine. Both cross into the brain and produce effects there.

Because that conversion must happen first, nothing occurs immediately. Onset is typically around an hour after dosing — a delay that clinicians build into their monitoring rather than something a patient should try to hurry.

Noribogaine’s other property matters just as much: it is long-acting. It remains present in the body for days after the acute experience has ended. This underpins the sustained reduction in cravings that patients describe in the days following treatment — and it is also why what someone takes in that period is a genuine medical risk rather than merely a relapse.

Dosing is calculated by body weight. In the hospital protocol behind the published Brazilian research, this is roughly 15 mg/kg of pure ibogaine for patients dependent on stimulants and 20 mg/kg for opioid-dependent patients.

Why withdrawal stops

This is ibogaine’s most immediate and most reliably observed effect, and it is the reason the compound entered addiction medicine at all.

Ibogaine interacts with a broad set of receptors in the brain, including opioid receptors. When it occupies those receptors, the withdrawal state resolves. In clinical practice the sequence is consistent: patients arrive in early withdrawal — visibly so, with the classic signs — and the withdrawal disappears first, before any other effect of the session has developed.

The historical origin of the entire field is this same observation. In 1962 Howard Lotsof, then heroin-dependent, reported that roughly a day after taking ibogaine he was neither in withdrawal nor craving.

What makes this clinically valuable is not just the relief. Conventional opioid detox is an ordeal that many people cannot complete, and the fear of it keeps people in dependence for years. Removing that barrier changes what is possible.

Ibogaine for opioid addiction →

Why cravings fall away

Stopping withdrawal is a pharmacological effect that other drugs can also achieve — methadone does it every day. What distinguishes ibogaine is what happens to craving.

Patients typically report that the compulsion itself — the constant preoccupation, the sense that using is not really a decision — is substantially reduced after a single session, and remains so for weeks or months rather than hours. In the published retrospective study co-authored by Dr. Rasmussen, patients treated once reported a median of 5.5 months of abstinence, and those treated more than once a median of 8.4 months.

The practical significance is easy to miss: the craving may go away, but a patient does not stop using merely because the craving is gone. Something has to fill the space that craving used to occupy. That is what the next section is about.

The introspective state

Alongside the physical effects, ibogaine produces a prolonged altered state that is unlike the classic psychedelics. It is often classified as an oneirogen — a “dream-inducer” — because what patients describe is closer to waking dreaming than to visual hallucination.

A characteristic experience, frequently reported by patients, is autobiographical: with eyes closed, memories appear as though projected on a screen, in colour and often in slow motion. These are not random images. Patients consistently report that what surfaces relates directly to the situations and problems they are actually dealing with — material they had not been able to access or make sense of before.

The phase begins about an hour after dosing and eases over the following hours; the acute period lasts around ten hours, with patients monitored for 24 to 48 hours.

Clinically, this state is not treated as a side effect or as the point of the treatment. It is treated as an opening.

The ibogaine experience →

Ibogaine as a psychotherapy facilitator

This is the framing used in the hospital programme that informs this article, and it is the most useful way to understand what ibogaine actually does.

In the programme behind the published research, ibogaine is not regarded as the treatment. It is regarded as what makes the treatment possible: it clears withdrawal, suppresses craving, and opens a period of unusual psychological accessibility — and then psychotherapy does the work of recovery within that window.

The protocol reflects this literally. Patients complete roughly four psychotherapy sessions before treatment and roughly four afterwards. Patients who do not wish to engage in psychotherapy are not accepted for treatment at all — the programme treats the psychological work as the part that sustains the result.

The parallel he draws is with MDMA-assisted therapy for PTSD. The compound is not the therapy; it is what allows the therapy to reach material it otherwise cannot.

This has a direct implication for anyone comparing programmes. A programme built around the session alone is offering the smaller half of the treatment.

What happens after ibogaine treatment →

How this differs from methadone and suboxone

The distinction is structural, not a matter of degree.

Methadone and buprenorphine are maintenance medications. They occupy opioid receptors continuously, taken daily, often for years. They are effective at stabilising people and preventing overdose deaths — but the dependence itself remains, and it is on the medication.

Ibogaine is given once. It interrupts the dependence rather than substituting for it, which is why many patients seek it specifically to come off maintenance therapy. That transition requires careful medical planning: patients on long-acting opioids are switched to a short-acting one before treatment, because ibogaine increases opioid toxicity and as little as possible should be circulating at the time of dosing.

Neither approach is universally superior, and this page is not the place to make that decision. But they are answering different questions.

Ibogaine vs methadone and suboxone →

What is still not known

Honesty here matters more than completeness.

Ibogaine’s full mechanism of action has not been established. It binds to an unusually wide range of receptor systems, and researchers have not settled which of those interactions account for which clinical effects. Research into whether ibogaine promotes neuroplasticity — changes in how neural connections form — is ongoing and genuinely promising, but it remains a line of investigation rather than a settled explanation.

The clinical evidence base is likewise limited. Ibogaine is not approved anywhere, formal trials have been difficult to run under prohibition, and most of what is published consists of observational and retrospective work rather than randomised controlled trials.

What can be said with confidence is narrower than what is often claimed for it: withdrawal interruption and craving reduction are consistently observed by clinicians and reported by patients, and the published outcomes are encouraging. That is not the same as a proven mechanism, and any source that presents it as one is overselling.

Ibogaine research and evidence →

What this means in practice

If ibogaine’s value lies in the window it opens rather than in the session itself, then the quality of a programme is determined by what it puts inside that window — psychological preparation beforehand, therapeutic support during recovery, and structured aftercare during the first months, when relapse risk is highest.

A programme that treats the session as the product is selling the least important part of it.

See which programmes include full psychological support

Free and confidential. We’ll review your case and set out suitable options — usually within 24 hours.

Sources

  1. Schenberg EE, de Castro Comis MA, Chaves BR, da Silveira DX. Treating drug dependence with the aid of ibogaine: a retrospective study. Journal of Psychopharmacology. 2014;28(11):993–1000. doi:10.1177/0269881114552713

Frequently asked questions

01. How does ibogaine work?
It converts in the liver to noribogaine; both act on multiple receptor systems including opioid receptors, stopping withdrawal and reducing cravings, while producing a prolonged introspective state.
02. How long does ibogaine take to work?
Effects typically begin around an hour after dosing, because the liver must convert it to noribogaine first.
03. What does ibogaine do to the brain?
It acts on a wide range of receptor systems including opioid receptors. The full mechanism is not yet established.
04. Does ibogaine reset the brain?
"Reset" is a simplification. Withdrawal and craving are interrupted, and research into neuroplasticity is ongoing — but no reset mechanism has been proven.
05. How does ibogaine stop withdrawal?
By interacting with opioid receptors, which resolves the withdrawal state — typically within the first hours of a session.
06. Is ibogaine the same as methadone?
No. Methadone is daily maintenance; ibogaine is a single supervised session intended to interrupt dependence rather than substitute for it.
07. Does ibogaine work without therapy?
In the protocol described here, no — psychotherapy is required before and after, and patients who decline it are not treated.

This article is for information only and is not medical advice. Ibogaine's mechanism is not fully established and it is not an approved medicine in most countries.

Get a free, confidential assessment

Our consultation is free for you. Medical decisions are made by the clinic's doctors.